Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IMMX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Dara-CyBorD | Light Chain (AL) Amyloidosis | Phase 3 · NCT07709715 | Not yet recruiting |
| Evarucabgene Autoleucel (NXC-201) | Light Chain (AL) Amyloidosis | Phase 3 · NCT07709715 | Not yet recruiting |
| Curcumin/Doxorubicin-encapsulating Nanoparticle… | Solid Tumor, Adult | Phase 1/2 · NCT03382340 | Unknown |
Also used in these trials (approved or third-party drugs, not IMMX's own candidates): Tislelizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
IMMX holds $336.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $12M/quarter from operations, an estimated runway of 83.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 45 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IMMX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| JANUS HENDERSON GROUP Ltd. | Institution (13G, 5%+) | 9,783,192 | 11.67% | 2026-06-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 4,539,819 | 5.42% | 2026-09-30 |
| Eventide Asset Management, LLC | Institution (13G, 5%+) | 3,891,019 | 4.64% | 2026-06-30 |
| Saturn V Capital Management LP | Institution (13G, 5%+) | 3,693,585 | 4.41% | 2025-12-26 |
| Yekaterina Chudnovsky Director · +78,500 options |
Insider | 3,247,326 | 3.87% | 2026-05-22 |
| Ilya M Rachman CEO and Chairman, Director · +1.18M options |
Insider | 1,141,683 | 1.36% | 2025-12-10 |
| Carey Ng Director · +78,500 options |
Insider | 1,051,471 | 1.25% | 2026-05-22 |
| Jason Hsu Director · +78,500 options |
Insider | 949,250 | 1.13% | 2026-05-22 |
| Nancy T Chang Director · +52,143 options |
Insider | 925,130 | 1.10% | 2026-05-22 |
| Gabriel S Morris CFO, President, Director · +1.18M options |
Insider | 315,570 | 0.38% | 2025-12-08 |
| Helen C. Adams Director · +78,500 options |
Insider | 181,004 | 0.22% | 2026-05-22 |
| Magda Marquet Director · +78,500 options |
Insider | 72,342 | 0.09% | 2026-05-22 |
Share count 83,812,456 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMMX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →